U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Female Reproductive System Carcinoma

MedGen UID:
1659396
•Concept ID:
C4727741
•
Neoplastic Process
Synonym: Refractory Female Reproductive System Cancer

Definition

Female reproductive system carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Female Reproductive System Carcinoma

Professional guidelines

PubMed

Treatment of human papillomavirus-associated vulvar disease with the CO2-laser. Physical and histological aspects with use of a new scanning device, the SwiftLase.
Spörri S, Frenz M, Altermatt HJ, Hannigan EV, Dreher E
Arch Gynecol Obstet 1996;259(1):25-35. doi: 10.1007/BF02505305. PMID: 8933926

Recent clinical studies

Etiology

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Int J Gynecol Cancer 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. PMID: 19574774
Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" human papilloma virus types in preinvasive cervical lesions.
Mourón SA, Abba MC, Güerci A, Gómez MA, Dulout FN, Golijow CD
Mutat Res 2000 Aug 21;469(1):127-34. doi: 10.1016/s1383-5718(00)00066-8. PMID: 10946249
Hormonal approach to breast cancer prevention.
Russo IH, Russo J
J Cell Biochem Suppl 2000;34:1-6. PMID: 10762007

Diagnosis

Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA
Mod Pathol 2021 May;34(5):983-993. Epub 2020 Oct 19 doi: 10.1038/s41379-020-00699-1. PMID: 33077920
Malignant transformation from mature cystic teratoma of the ovary.
Shimada T, Higashijima A, Fukushima A, Komatsu N, Noguchi M, Ohashi K, Hasegawa Y, Miura K
J Obstet Gynaecol Res 2019 Sep;45(9):1957-1960. Epub 2019 Jun 19 doi: 10.1111/jog.14043. PMID: 31215124
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC, Sung PL, Hsieh SL, Chou YT, Lee OK, Wu CW, Wang PH
Oncotarget 2017 Apr 25;8(17):29013-29027. doi: 10.18632/oncotarget.15994. PMID: 28423672Free PMC Article
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article

Therapy

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD
BMC Cancer 2011 Jun 22;11:263. doi: 10.1186/1471-2407-11-263. PMID: 21693061Free PMC Article

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA
Mod Pathol 2021 May;34(5):983-993. Epub 2020 Oct 19 doi: 10.1038/s41379-020-00699-1. PMID: 33077920
Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.
Monk BJ, Herzog TJ, Tewari KS
Curr Pharm Des 2016;22(30):4717-4728. doi: 10.2174/1381612822666160505114326. PMID: 27145761Free PMC Article
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA
Gynecol Oncol 2015 Nov;139(2):236-41. Epub 2015 Sep 25 doi: 10.1016/j.ygyno.2015.09.016. PMID: 26404183Free PMC Article

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
New concept in urologic surgery: The total extended genital sparing radical cystectomy in women.
Cisternino A, Capone L, Rosati A, Latiano C, Sebastio N, Colella A, Cretì G
Arch Ital Urol Androl 2023 May 22;95(2):11058. doi: 10.4081/aiua.2023.11058. PMID: 37212881
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.
Monk BJ, Herzog TJ, Tewari KS
Curr Pharm Des 2016;22(30):4717-4728. doi: 10.2174/1381612822666160505114326. PMID: 27145761Free PMC Article
Hormonal approach to breast cancer prevention.
Russo IH, Russo J
J Cell Biochem Suppl 2000;34:1-6. PMID: 10762007

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...